Utility of immune checkpoint inhibitors in non‐small‐cell lung cancer patients with poor performance status

Most clinical trials of non‐small‐cell lung cancer (NSCLC) exclude patients with poor ECOG performance status (PS). Thus, the efficacy of immune checkpoint inhibitors (ICIs) in patients with poor PS remains unclear. Herein, we used data from a retrospective cohort to assess the potential clinical be...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Sci
Main Authors: Kano, Hirohisa, Ichihara, Eiki, Harada, Daijiro, Inoue, Koji, Kayatani, Hiroe, Hosokawa, Shinobu, Kishino, Daizo, Watanabe, Kazuhiko, Ochi, Nobuaki, Oda, Naohiro, Hara, Naofumi, Ninomiya, Kiichiro, Hotta, Katsuyuki, Maeda, Yoshinobu, Kiura, Katsuyuki
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2020
Assuntos:
Clinical Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7540975/
https://ncbi.nlm.nih.gov/pubmed/32726470
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.14590
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados